Jefferies Lowers Numbers on Impax Laboratories (IPXL)

June 25, 2012 8:08 AM EDT Send to a Friend
Get Alerts IPXL Hot Sheet
Price: $30.79 +2.87%

Rating Summary:
    7 Buy, 11 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 21 | Down: 43 | New: 52
Trade IPXL Now!
Join SI Premium – FREE
Jefferies lowered estimates and its price target on Impax Laboratories (NASDAQ: IPXL) from $21.00 to $20.00 citing AXR competition.

The firm comments, "We've been uneasy with IPXL geared to Gx AXR revenues at risk of competition and ending completely in ’14. News of Actavis/WPI’s AXR approval means an immediate hit to ’12-’14 REV, partially offset by lower royalty payout. This might pave the way for IPXL’s own AXR approval but we doubt it – some speculate Concerta as well – but certain losses trump uncertain gains."

FY12 EPS goes from $1.92 to $1.88 and FY13 goes from $1.42 to $1.29.

For an analyst ratings summary and ratings history on Impax Laboratories click here. For more ratings news on Impax Laboratories click here.

Shares of Impax Laboratories closed at $22.85 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change

Related Entities

Jefferies & Co

Add Your Comment